EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Sanofi (SNY) had EBITDA Margin of 30.75% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$52.85B |
|
$8.84B |
|
$14.76B |
|
$38.09B |
|
$43.02B |
|
$9.83B |
|
$-2.84B |
|
$6.99B |
|
$9.52B |
|
$5.81B |
|
$5.63B |
|
$8.88B |
|
$8.77B |
|
$9.83B |
|
$16.25B |
|
2.44B |
|
2.45B |
|
$3.62 |
|
$3.60 |
|
| Balance Sheet Financials | |
$35.02B |
|
$11.37B |
|
$108.45B |
|
$143.47B |
|
$32.07B |
|
$16.12B |
|
$30.26B |
|
$62.33B |
|
$81.13B |
|
$4.69B |
|
$81.13B |
|
2.44B |
|
| Cash Flow Statement Financials | |
$12.16B |
|
$-2.77B |
|
$-9.29B |
|
$8.42B |
|
$8.66B |
|
$244.38M |
|
-- |
|
$-5.44B |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.09 |
|
-- |
|
-- |
|
0.17 |
|
0.26 |
|
72.07% |
|
18.60% |
|
18.60% |
|
|
EBITDA Margin |
30.75% |
13.22% |
|
16.72% |
|
$9.12B |
|
-- |
|
-- |
|
-- |
|
0.37 |
|
1.28 |
|
5.30 |
|
68.81 |
|
6.94% |
|
119.96% |
|
3.92% |
|
5.79% |
|
$33.26 |
|
$3.72 |
|
$4.96 |
|